Infectious Diseases Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis
Conditions: Fascioliasis Interventions: Drug: Oxfendazole; Drug: Triclabendazole Sponsors: Universidad Peruana Cayetano Heredia; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials

Integrating Hypertension Management in DSD for HIV
Conditions: Hypertension, HIV and Community Anti-retro-viral Treatment Interventions: Behavioral: Screening and treatment of hypertension among PLHIV in DSD models for HIV Sponsors: Infectious Diseases Research Collaboration, Uganda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials

Assessing the Impact of a Digital VMMC Platform
Conditions: Voluntary Medical Male Circumcision Interventions: Other: VMMC NEXUS Digital application Sponsors: University of Alabama at Birmingham; Centre for Infectious Disease Research in Zambia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials

Collaborative Open Research Initiative Study (CORIS-1)
Conditions: Patient Engagement; COVID-19; Preventable Disease, Vaccine; Burnout, Professional; Emerging Infectious Disease; Artificial Intelligence; Climate Change; Online Education; Mental Health Issue; Substance Use Disorders Interventions: Other: No intervention. This is an observational study Sponsors: Chisquares Incorporated Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19
Conditions: COVID-19; Azvudine Interventions: Drug: Azvudine; Drug: Paxlovid Sponsors: The First Affiliated Hospital of Zhengzhou University; Henan Provincial Chest Hospital; The Affiliated Infectious Disease Hospital of Zhengzhou University; The Fifth People ' s Hospital of Anyang; Shangqiu Municipal Hospital; Nanyang Central Hospital; Luoyang Central Hospital; Guangshan County People ' s Hospital; Fengqiu County People ' s Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials

The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy
Conditions: Falciparum; Malaria Interventions: Drug: Artemether-lumefantrine; Drug: Dihydroartemisinin-Piperaquine Sponsors: Infectious Diseases Research Collaboration, Uganda; London School of Hygiene and Tropical Medicine; Radboud University Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Conditions: Lymphohistiocytosis, Hemophagocytic; Secondary Hemophagocytic Lymphohistiocytosis; Macrophage Activation Syndrome; Hyperinflammatory Syndromes Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials

Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses
Conditions: HIV Infections; HBV Coinfection Interventions: Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) Sponsors: ANRS, Emerging Infectious Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials

Cali Sin Tos Aim 2
Conditions: Tuberculosis Interventions: Device: Chatbot; Diagnostic Test: Oral testing Sponsors: Yale University; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
Conditions: HIV-1-infection; Pregnancy; Postpartum Interventions: Drug: CAB LA 600mg; Drug: RPV LA 900mg; Drug: CAB LA 400mg; Drug: RPV LA 600mg Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.
Conditions: HIV Interventions: Biological: 16055 NFL delta Gly4 trimer; Biological: Trimer 4571; Biological: Ad4-Env145NFL, 5 x 108 viral particles (vp) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials

TREATment of Lower Respiratory Tract Infection in Sri Lanka (TREAT-SL)
Conditions: Lower Resp Tract Infection Interventions: Other: electronic clinical decision support tool (eCDST) diagnostic plan Sponsors: Duke University; National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials

Invivyd Announces FDA Authorization for Emergency Use of Pemgarda (Formerly VYD222) for Pre-Exposure Prophylaxis (PrEP) of COVID-19
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that Pemgarda™ (pemivibart), formerly... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 22, 2024 Category: Pharmaceuticals Source Type: clinical trials

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
Conditions: Chronic Granulomatous Disease (CGD); X-Linked Chronic Granulomatous Disease Interventions: Biological: Base-edited hematopoietic stem and progenitor cells; Drug: Busulfan; Drug: Palifermin; Drug: Filgrastim; Drug: Plerixafor Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials

Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms
Conditions: HIV Infections Interventions: Biological: Blood sampling Sponsors: ANRS, Emerging Infectious Diseases; Centre Pasteur du Cameroun; Centre M ère et Enfant de la Fondation Chantal Biya; Centre Hospitalier D ' essos; Hospital General De Douala; Centre Hospitalier Universitaire d ' Orl éans; Institut Pasteur; Hopital Universitaire Robert-Debre; Université Paris-Sud Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials